Savara Inc.: Orphan lung disease co. Molgradex, Ph 3, inhaled GM-CSF: autoimmune pulmonary alveolar proteinosis (aPAP), Ph 2a: nontuberculous mycobacteria (NTM) lung infection, and prep for Ph 2a in CF affected individuals w chronic NTM lung infection; and AeroVanc, Ph 3 inhaled vancomycin for persistent MRSA lung infection in CF. Expanding pipeline through indication expansion, strategic devt partnerships and product acqs. Most recent acquisition is aerosolized amikacin/fosfomycin, Phase 2 ready, proprietary combination antibiotic (demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens).
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Phase III
Disease Space
Fibrosis, Rare Disease, Respiratory
Finance
Pre-Revenues
Industry
Biotechnology, Life Sciences
Listing
Public, USA
Market Cap
100MM - 500MM
Website:
Address:
6836 Bee Cave Road
Building 3, Suite 200
Austin, TX 78746
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Clients at Jefferies

New York, NY, United States, June 4 – June 7, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.